chrisvoncsefalvay/vaers-outcomes huggingface dataset:
08/19/2007 Had severe pain in left arm above, below and at site of injection with in an hour. Took 3 reg ADVIL, used heat on arm and went to bed. On 08/20/2007, awoke with severe pain in left arm from top of shoulder to elbow then into fingertips, intolerable headache, dizziness, fever 100.5, nausea, gagging, very weak and eye pain. Went to urgent care to report reaction with physicians office. Suggested rest, ice and Benadryl. 08/23/2007 Arm becoming more swollen and redness expanding further into the arm. Visited doctor at clinic on 08/23/2007 with reaction measured sizes of 10x10 cm swelling, 4x6 cm redness. Reported this reaction to both clinic and to my regular clinic. Physician advised to continue resting, use ice and drink plenty fluids. Two weeks after Tdap shot regained most of my physical strength with continued pain and weakness in left arm. Pain in left arm muscle continued for another month after doctors visit on 08/23/2007, but eventually subsided as all the swelling in the muscle dissipated.
headache; sweaty; Feverish; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (sweaty), PYREXIA (Feverish) and HEADACHE (headache) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Mar-2021, the patient experienced HYPERHIDROSIS (sweaty) and PYREXIA (Feverish). On 14-Mar-2021, the patient experienced HEADACHE (headache). At the time of the report, HYPERHIDROSIS (sweaty), PYREXIA (Feverish) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.   Treatment information was not provided.   Reporter did not allow further contact
Doctor ordered PCV 20 and Covid vaccine for patient on 11/22/20222. COVID vaccine was not available. Patient was accidently given Flu vaccine at 0830 on 11/22/2022 instead of PCV 20. Patient remained in office 15-20 minutes after given vaccine. No reactions occurred. Patient decided to wait to get vaccines (PCV 20 and Covid) at a later date.
Pt. states that after receiving the 1st dose of Moderna 08/25/2021, started experiencing symptoms 09/01/2021 of an itchy rash developing in and around the injection site. Entire left side of injection site covered in hives. No Primary visit noted. Still continuing to experience symptoms.
What are side effects after the third dose/had received the Moderna COVID-19 Vaccine and experienced a side effect.; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (What are side effects after the third dose/had received the Moderna COVID-19 Vaccine and experienced a side effect.) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (What are side effects after the third dose/had received the Moderna COVID-19 Vaccine and experienced a side effect.). At the time of the report, VACCINATION COMPLICATION (What are side effects after the third dose/had received the Moderna COVID-19 Vaccine and experienced a side effect.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported. No treatment information reported.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. On or around 19-APR-2017, the patient was inoculated with the ZOSTAVAX (lot number, dosage and route of administration not provided) for its intended purpose: the prevention of shingles. Shortly thereafter, the patient suffered swelling of face, acute respiratory distress, serious pain in her right leg that radiated down her leg, and right sided facial pain. In or around May 2017, the patient presented to her physician for this injury and was diagnosed with compression of right sciatic nerve and trigeminal neuralgia. As a direct and proximate result of the ZOSTAVAX, the patient's symptoms have resulted in physical limitations not present prior to ZOSTAVAX. The patient has also experienced mental and emotional distress due to resulting physical limitations and the seriousness of her condition. As a result of the ZOSTAVAX, the patient sustained severe and permanent personal injuries. Further, as a tragic consequence, the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result, the patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the events were considered to be not recovered. Acute respiratory distress, swelling of face, compression of right sciatic nerve and trigeminal neuralgia were considered disabling. Upon internal review,  acute respiratory distress was determined to be medically significant. Additional information has been requested.
Initial unsolicited information received from a physician and consumer (mother) via phone call on 15-May-2018. This case involves a two-month-old male patient who was vaccinated once with a 0.5 mL dose of a DAPTACEL (batch number: C5102BA, expiry date not reported) intramuscularly in thigh and a dose of ROTAVIRUS VACCINE (batch number, expiry date, dose, route and site of administration were not reported) on 10-Apr-2018. The patient's past medical history and concomitant medication was not provided. On an unknown date, post vaccination, the patient developed palsy (paralysis). The patient was evaluated by his physician on 29-Apr-2018. Relevant lab investigations and corrective treatment were not reported. The outcome of the event was reported as Unknown. Upon internal review the case was considered as serious because of important medical event. The physician assessed that the cause of the event was the DTAP vaccine. List of documents held by sender: none.; Sender's Comments: Sanofi company comment dated 24-05-2018: This case involves a two-month-old male patient who developed paralysis while he got vaccinated with diphtheria-15/tetanus/5 AC pertussis vaccine. This case cannot be assess due to lack of information. Moreover, information regarding relevant medical history, concurrent conditions, concomitant medications and family history will aid in comprehensive assessment of this case.
received the shingles vaccination still got them/suspected vaccination failure; Shingles on shoulder and hip; Painful; Itchy; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Family history included shingles (mother).   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: received the shingles vaccination still got them/suspected vaccination failure) (serious criteria GSK medically significant), shingles (Verbatim: Shingles on shoulder and hip), pain (Verbatim: Painful) and pruritus (Verbatim: Itchy). The outcome of the vaccination failure was unknown and the outcome of the shingles, pain and pruritus were not recovered/not resolved.   It was unknown if the reporter considered the vaccination failure, shingles, pain and pruritus to be related to Shingles vaccine.     It was unknown if the company considered the vaccination failure, shingles, pain and pruritus to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 10-MAR-2023 This case was reported by a patient via interactive digital media. The patient reported that his/her mother had shingles so he/she received Shingles vaccine and still experienced shingles on his/her right shoulder and hip. The patient stated that the shingles are not as painful as his/her mother but they are still itchy and painful. This case was considered as suspected vaccination failure as details regarding completion of primary schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting. Follow-up would not possible as no contact details were available.
Patient was administered COVID vaccine while in ER for monitoring of possible reaction. Per ER report: "Pt noted to be having reaction, pt with decreasing level of consciousness (groggy), did answer questions. Epi/Benadryl given from bedside. VSS at that  time. Currently speech is slow but does answer appropriately."  Patient was discharged home.
fever 103 R; non stop crying for 24 hrs following inject; pt sent to lab for CBC & blood culture;
Member administered HEP A vaccine. After vaccination, it was discovered that vaccine was expired. Expiration was 9/11/2018. Member monitored and zero adverse reactions noted.
This is an instance of breakthrough COVID-19 disease after which death occurred.   The individual was vaccinated with the Moderna product on 02/10/2021, 03/10/2021, and 09/23/2021. They first tested positive via antigen test on 02/01/2022 as a part of assisted living facility outbreak testing. At that time, they were described as "asymptomatic." They tested positive for COVID-19 again on 02/13/2022 and 02/24/2022 when being admitted to hospital. They remained hospitalized until their death on 03/04/2022.   The individual had listed allergies to Measles Vaccine, Mumps Vaccine, Rubella Vaccine, MMR Vaccine, and Zoster Vaccine but the nature/reaction of these allergies was not listed in the health link system.
Initial misuse report received from healthcare professional on 22 October 2013. The cases were received on 21 Mar 2014. A 67-year-old female patient received FLUZONE (no other information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none.
Swollen, red, hot area of arm - size of silver dollar. Soreness, some low grade fever, flushed feeling.
He received Pfizer Covid Vaccines on 2/6/21 and 2/26/21. He was admitted on 9/11/21 due to abdominal pain, productive cough, and fever. On hospital day number 4, he is on room air with Saturation of 94%.
Spontaneous report received on November 16, 2000, from Medical Assistant in a Dermatologist office, regarding adverse event possibly related to administration of Fluvirin. On October 06, 2000, this 83 year old female received a Fluvirin injection. "Shortly after" receiving the injection, she developed a temperature of 102 degrees, chills and general malaise. These symptoms lasted approximately four days. In mid October, she developed lesions on her hands and in her mouth. She was treated with an unspecified course of Prednisone, with symptom abatement. After completion of the Prednisone therapy, the symptoms reappeared. She was then treated with an injection of Kenalog and topical use of Orobase and Kenalog ointments; lesions remain at the time of this report. The diagnosis of Stevens Johnson Syndrome has been made. The reporter stated that the Dermatologist's office has treated this patient for over ten years. She indicates that the pt is normally very "mentally there" but that the pt "hasn't been herself". She describes pt as being "easily confused and forgetful".  Additional information has been requested from the physician. Follow up information from Primary care physician received on October 11, 2001 by Evans Vaccines: "The additional adverse events of sore throat and swollen lip were identified. PT has resolution of symptoms by November 20, 2000. Dosages and therapy dates of concomitant medications were clarified.
Two weeks post vaccination, on approximately 12/08/2000, the patient developed a mild rash which was described as a mild case of chicken pox by the physician and also a generalized skin rash with no lesions, by the nurse. The rash lasted 24 hours and it was noted that there were no remaining specimens for testing. The patient sought unspecified medical attention. The child's mother also had an experience following exposure to varicella virus vaccine live. Additional information is not expected.
developed pain in my left arm; Within two weeks it was so painful I could not move out of bed; Within two weeks it was so painful I could not move out of bed; developed myofascial and now it is into lymphodemia  also; developed myofascial and now it is into lymphodemia  also; have nerves that are entrapped and numbness in arm and fingers.; have nerves that are entrapped and numbness in arm and fingers.; unable to work; have nerves that are entrapped and numbness in arm and fingers.; This is a spontaneous report from a contactable consumer (patient) or other non hcp.   A 59-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: Er8737 and expiry date: unknown), dose 1 via an unspecified route of administration, administered in Arm Left on 02Apr2021 at 10:00 as DOSE 1, SINGLE for covid-19 immunisation. Medical history included Crohns disease. Concomitant medications included anastrozole, propranolol, and azathioprine. The patient previously took sulfa 12 and experienced drug hypersensitivity, humarap and experienced drug hypersensitivity. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 08Apr2021 at 12:00, the patient developed pain in left arm. Within two weeks it was so painful she could not move out of bed. She developed myofascial and now it is into lymphodemia also. Also have nerves that are entrapped and numbness in arm and fingers. She was unable to work. The outcome of all the events was not recovered.
Dizziness, Headache, Myalgia, Arthralgia, Fever, CHILLS, FATIGUE Narrative:
Severe headache began about 24 hours post vaccine accompanied by nausea (for about an hour), chills, fever and fatigue. Headache lasted 12+ hours. AEs required I sleep or lay down from 2:30pm until I went to sleep around 11:30pm. The fatigue was as bad as my headache. Today is Saturday, July 25th and I feeling much better - headache is very mild and fatigue is vastly improved. Chills, fever, nausea all gone.
red patch that is about 3 inches above the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (red patch that is about 3 inches above the injection site) in a 90-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021, the patient experienced VACCINATION SITE ERYTHEMA (red patch that is about 3 inches above the injection site). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) at a dose of 500 mg. At the time of the report, VACCINATION SITE ERYTHEMA (red patch that is about 3 inches above the injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant Concomitant Medications were reported.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Patient received shots on 5/25/2004 (Pediarix and PCV7) abd the next day went to private MD because she awoke with a rash on face and all over her body.  No fever reported, normal appetite.  Doing well otherwise.
This spontaneous report as received from a other health professional refers to a 16 year old male patient. On 09-MAY-2014 the patient was vaccinated with GARDASIL dose 1, 05.5 milliliters, intramuscularly. On 01-JUL-2014, the patient received the second dose of and the third dose on 15-JUL-2014. The patient experienced no adverse effect. Additional information has been requested.
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 20-JUN-2016 the patient was vaccinated with an improperly stored dose of GARDASIL single-dose vial (SDV) lot # L035105 expiration date 14-MAY-2017, dose and route were unspecified. This specified lot number vaccine was exposed to temperature excursion twice. The total cumulative excursion time of the first time was 24 hours with the lowest recorded temperature of 9 Fahrenheit degree (also reported as Celsius degree). The total cumulative excursion time of the second time was 24 hours with the lowest recorded temperature of 8.7 Fahrenheit degree (also reported as Celsius degree). The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effect was reported. This is one of several reports received from the same source. Additional information has been requested.
On 12/7/11 mom noticed child leg seemed tender - when she checked it right leg had a red, hard lump and was warm to touch. Leg was fine yesterday (12-6-11). Seen in office 12-7-11 - Dx cellulitis & abscess - other serum reaction due to vaccination. Started on OMNICEF x 5 days & EPSOM salt soaks - recheck 12/8/11. Missed f/u appt - was looking better when last talked to mom.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55-year-old male patient received BNT162b2 (BNT162B2), on 17Aug2022 at 12:00 as dose number 3 (booster), single (Batch/Lot number: unknown) at the age of 54 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "No" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: No other medication in 2 weeks. Paxlovid Treatment received for COVID 19 from 28Nov2022 to 02Dec2022. No Known allergies. No other medical history.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Initially, back pain was all along spine.  Later pain concentrated in lower back around base of spine. Pain radiated outward from base of spine to hips.  It hurt to sit down as a shooting pain would occur down my left leg.  It hurt to lie down because of the pain on my sides (hips).  Later, I began to get tingling and numbness in my legs and feet, especially my right leg. This was most pronounced when trying to sit down, but the symptoms existed in a milder form when lying down or even standing. This course of events has taken place over the past several days. All symptoms have been moderate or mild in intensity.   The lower back / base of spine  pain and other symptoms continues.
It was reported that a male pt received a TD Adult (right arm), a MMR (left arm) and a Hep B (left arm) vaccinations on 08/28/2000. Sometime after the vaccinations the pt developed a "Arthrus reaction." No specifics were provided, further info requested. From additional info received on 11/14/2000, it was reported that the pt developed swelling of the right arm into armpit, increased pain, loss of appetite, no vomiting, no fever. Reportedly the pt recovered from his experience. No further info is expected, this case is closed.
This spontaneous report as received from a nurse regarding an unspecified number of patients of unknown age. There was no information about concurrent condition and historical medication. On 07-AUG-2015, the patients were vaccinated with improperly stored PNEUMOVAX 23 lot # L008664, expiration date 03-NOV-2016 and lot # K008409, expiration date 04-MAR-2016 and lot # K018528, expiration date 14-APR-2016. No concomitant medication was reported. No adverse event was reported. No PQC (product quality complaint) was involved. The outcome of the event was unknown. This is one of several reports received from the same reporter. Additional information has been requested.
pt recvd 1 dose of Engerix-B & same day exp fever & vomiting which lasted until the next day 24JUL92; no tx was given;
About two day after the vaccine was given, right shoulder and deltoid pain with movement of my arm to the side or behind me.  The pain has continued to progress and worsen over 2 weeks, not able to move my arm away from my body if my palm is facing posteriorly.  MD appt on Monday 9/27 with employee health
Information has been received from a physician and a nurse concerning a male with diabetes and sulfa allergy who on 06-AUG-2007 was vaccinated with ZOSTAVAX (Lot # 657764/0584U). Concomitant therapy included FLOMAX and ezetimibe (+) simvastatin (MSD). The nurse reported on 09-AUG-2007 the patient developed shingles lesions on the left side of his back. The physician reported that on 13-AUG-2007 the patient presented to her office with 2 - 3 vesicles at the T6 dermatome site. He was also complaining of pain. He was treated with DARVOCET and gabapentin. The physician stated that she saw the patient again in her office on 21-AUG-2007 and he was recovering. The lesions were dried and he had no further pain. She stated there was no specimen to be sent as the patient was recovering. The physician did not feel the patient's symptoms were caused by the vaccine. This is one of several reports from the same source. Additional information has been requested.
migraine; hands tingling; This spontaneous case was reported by a consumer and describes the occurrence of MIGRAINE (migraine) and PARAESTHESIA (hands tingling) in a 49-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039KZOA) for COVID-19 vaccination.     No Medical History information was reported.   On 04-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Feb-2021, the patient experienced MIGRAINE (migraine) and PARAESTHESIA (hands tingling). At the time of the report, MIGRAINE (migraine) and PARAESTHESIA (hands tingling) outcome was unknown. Patient received the second dose of Moderna COVID-19 vaccine yesterday and started experiencing migraine and hands tingling. Inquires if hands tingling is a common adverse event regarding the vaccine.          Concomitant product use was not provided by the reporter. No treatment information was provided.